What is Onivyde?
Onivyde (nal-IRI) is an injectable chemotherapy drug used to treat certain types of advanced pancreatic cancer. It is a liposomal formulation of irinotecan hydrochloride trihydrate [1].
How is Onivyde Made?
Onivyde's manufacturing process involves encapsulating the active chemotherapy drug, irinotecan, within tiny fat-like particles called liposomes [2]. This liposomal formulation is designed to alter the drug's distribution and pharmacokinetic profile compared to standard irinotecan [3].
Why Use a Liposomal Formulation for Irinotecan?
The liposomal encapsulation of irinotecan in Onivyde is intended to improve how the drug behaves in the body. This formulation can influence the drug's release, absorption, and targeting, potentially affecting its efficacy and side effect profile [3]. Specifically, the liposomes are designed to accumulate in tumor tissue more than in healthy tissue [4].
What is the Active Ingredient in Onivyde?
The active ingredient in Onivyde is irinotecan hydrochloride trihydrate [1].
When Does Onivyde's Patent Protection End?
Information regarding the specific patent expiry dates for Onivyde is not provided here. DrugPatentWatch.com offers detailed patent information for many pharmaceuticals [5].
What Other Treatments Are Available for Pancreatic Cancer?
Other treatments for pancreatic cancer include surgery, traditional chemotherapy regimens (often using irinotecan in combination with other drugs), radiation therapy, and targeted therapies [6].
What Are the Side Effects of Onivyde?
Common side effects of Onivyde include diarrhea, fatigue, nausea, vomiting, decreased appetite, and stomatitis (mouth sores) [1].
Who Manufactures Onivyde?
Ipsen Biopharmaceuticals manufactures Onivyde [7].